Clinical trial
Effect of Pyridorin in Patients With Diabetic Nephropathy
NCT00320021 · BioStratum, Industry · Completed
Key facts
| NCT number | NCT00320021 |
|---|---|
| Title | Effect of Pyridorin in Patients With Diabetic Nephropathy |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Escalating Dose, Pilot Study to Evaluate the Safety, Tolerability and Biologic Activity of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes |
| Lead sponsor | BioStratum, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | Pyridorin (pyridoxamine dihydrochloride) |
| Enrollment | 80 |
| Start date | Jul 1, 2002 |
| Completion | Sep 1, 2003 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 27, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: